135 related articles for article (PubMed ID: 33460663)
21. mTOR inhibition potentiates cytotoxicity of Vγ4 γδ T cells via up-regulating NKG2D and TNF-α.
Cao G; Wang Q; Li G; Meng Z; Liu H; Tong J; Huang W; Liu Z; Jia Y; Wei J; Chi H; Yang H; Zhao L; Wu Z; Hao J; Yin Z
J Leukoc Biol; 2016 Nov; 100(5):1181-1189. PubMed ID: 27256566
[TBL] [Abstract][Full Text] [Related]
22. Enhanced susceptibility of adriamycin-treated human renal cell carcinoma cells to lysis by peripheral blood lymphocytes and tumor infiltrating lymphocytes.
Wu XX; Zeng Y; Jin XH; Kakehi Y
Oncol Rep; 2007 Aug; 18(2):353-9. PubMed ID: 17611656
[TBL] [Abstract][Full Text] [Related]
23. Tumor-promoting versus tumor-antagonizing roles of γδ T cells in cancer immunotherapy: results from a prospective phase I/II trial.
Kunzmann V; Smetak M; Kimmel B; Weigang-Koehler K; Goebeler M; Birkmann J; Becker J; Schmidt-Wolf IG; Einsele H; Wilhelm M
J Immunother; 2012; 35(2):205-13. PubMed ID: 22306909
[TBL] [Abstract][Full Text] [Related]
24. Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application.
Miyashita M; Shimizu T; Ashihara E; Ukimura O
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445615
[TBL] [Abstract][Full Text] [Related]
25. Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma.
Kobayashi H; Tanaka Y; Yagi J; Minato N; Tanabe K
Cancer Immunol Immunother; 2011 Aug; 60(8):1075-84. PubMed ID: 21519826
[TBL] [Abstract][Full Text] [Related]
26. In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells.
Niu C; Jin H; Li M; Xu J; Xu D; Hu J; He H; Li W; Cui J
BMC Immunol; 2015 Oct; 16():61. PubMed ID: 26458364
[TBL] [Abstract][Full Text] [Related]
27. Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD8O) costimulation.
Wang YC; Zhu L; McHugh R; Graham SD; Hillyer CD; Dillehay D; Sell KW; Selvaraj P
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):1-8. PubMed ID: 9147700
[TBL] [Abstract][Full Text] [Related]
28. Decitabine Inhibits Gamma Delta T Cell Cytotoxicity by Promoting KIR2DL2/3 Expression.
Niu C; Li M; Zhu S; Chen Y; Zhou L; Xu D; Li W; Cui J; Liu Y; Chen J
Front Immunol; 2018; 9():617. PubMed ID: 29632540
[TBL] [Abstract][Full Text] [Related]
29. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
[TBL] [Abstract][Full Text] [Related]
30. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
Igarashi T; Wynberg J; Srinivasan R; Becknell B; McCoy JP; Takahashi Y; Suffredini DA; Linehan WM; Caligiuri MA; Childs RW
Blood; 2004 Jul; 104(1):170-7. PubMed ID: 15016654
[TBL] [Abstract][Full Text] [Related]
31. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.
Griffith TS; Fialkov JM; Scott DL; Azuhata T; Williams RD; Wall NR; Altieri DC; Sandler AD
Cancer Res; 2002 Jun; 62(11):3093-9. PubMed ID: 12036919
[TBL] [Abstract][Full Text] [Related]
32. Sunitinib Induces NK-κB-dependent NKG2D Ligand Expression in Nasopharyngeal Carcinoma and Hepatoma Cells.
Huang YX; Chen XT; Guo KY; Li YH; Wu BY; Song CY; He YJ
J Immunother; 2017 Jun; 40(5):164-174. PubMed ID: 28452850
[TBL] [Abstract][Full Text] [Related]
33. NK cells use NKG2D to recognize a mouse renal cancer (Renca), yet require intercellular adhesion molecule-1 expression on the tumor cells for optimal perforin-dependent effector function.
Abdool K; Cretney E; Brooks AD; Kelly JM; Swann J; Shanker A; Bere EW; Yokoyama WM; Ortaldo JR; Smyth MJ; Sayers TJ
J Immunol; 2006 Aug; 177(4):2575-83. PubMed ID: 16888019
[TBL] [Abstract][Full Text] [Related]
34. Ganglioside DSGb5, preferred ligand for Siglec-7, inhibits NK cell cytotoxicity against renal cell carcinoma cells.
Kawasaki Y; Ito A; Withers DA; Taima T; Kakoi N; Saito S; Arai Y
Glycobiology; 2010 Nov; 20(11):1373-9. PubMed ID: 20663960
[TBL] [Abstract][Full Text] [Related]
35. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
36. Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid.
Idrees AS; Sugie T; Inoue C; Murata-Hirai K; Okamura H; Morita CT; Minato N; Toi M; Tanaka Y
Cancer Sci; 2013 May; 104(5):536-42. PubMed ID: 23387443
[TBL] [Abstract][Full Text] [Related]
37. [Antitumor response induced by vaccine of autologous dendritic/tumor fusion cells against renal cell].
Zhou J; Xia JC; Wang H; Wang QJ; Huang LX; Li YQ; Chen SP; Zhou FJ
Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):411-4. PubMed ID: 17974271
[TBL] [Abstract][Full Text] [Related]
38. The NKG2D ligand ULBP4 binds to TCRgamma9/delta2 and induces cytotoxicity to tumor cells through both TCRgammadelta and NKG2D.
Kong Y; Cao W; Xi X; Ma C; Cui L; He W
Blood; 2009 Jul; 114(2):310-7. PubMed ID: 19436053
[TBL] [Abstract][Full Text] [Related]
39. Matrix metallopeptidase 2 (MMP2) mediates MHC class I polypeptide-related sequence A (MICA) shedding in renal cell carcinoma.
Yang FQ; Liu M; Yang FP; Zhang XL; Yang B; Guo CC; Huang JH; Che JP; Yan Y; Zheng JH
Actas Urol Esp; 2014 Apr; 38(3):172-8. PubMed ID: 24461475
[TBL] [Abstract][Full Text] [Related]
40. Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma.
Niu C; Jin H; Li M; Zhu S; Zhou L; Jin F; Zhou Y; Xu D; Xu J; Zhao L; Hao S; Li W; Cui J
Oncotarget; 2017 Jan; 8(4):5954-5964. PubMed ID: 27992381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
